Malaria treatment efficacy among people living with HIV: The role of host and parasite factors

American Journal of Tropical Medicine and Hygiene

Volumn 77, Issue 4, 2007, Pages 627-632

  Laufer, Miriam K ^a,b   Van Oosterhout, Joep J G ^c   Thesing, Phillip C ^d   Dzinjalamala, Fraction K ^d   Hsi, Teresa ^b   Beraho, Lorraine ^b   Graham, Stephen M ^e   Taylor, Terrie E ^f   Plowe, Christopher V ^b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MALAWI   (Malawi)

^d Blantyre Malaria Project   (Malawi)

^e MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^f MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FANSIDAR; MOLECULAR MARKER; ANTIMALARIAL AGENT; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; NONHUMAN; RISK ASSESSMENT; TREATMENT FAILURE; ADOLESCENT; COHORT ANALYSIS; DRUG COMBINATION; ENDEMIC DISEASE; FEMALE; IMMUNE DEFICIENCY; IMMUNOLOGY; LONGITUDINAL STUDY; MALAWI; MALE; MULTIDRUG RESISTANCE; PARASITEMIA; PARASITOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; ANTIMALARIALS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE; ENDEMIC DISEASES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LONGITUDINAL STUDIES; MALARIA; MALAWI; MALE; PARASITEMIA; PYRIMETHAMINE; SULFADOXINE; TREATMENT OUTCOME;

EID: 38449087184     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2007.77.627     Document Type: Article

References (21)

1. French N, Nakiyingi J, Lugada E, Watera C, Whitworth JAG, Gilks CF, 2001. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 15: 899-906.
2. Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, Omoding N, Okongo M, Malamba S, Ojwiya A, 2000. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 356: 1051-1056.
3. Laufer MK, van Oosterhout JJ, Thesing PC, Thumba F, Zijlstra EE, Graham SM, Taylor TE, Plowe CV, 2006. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis 193: 872-878.
4. Colebunders R, Bahwe Y, Nekwei W, Ryder R, Perriens J, Nsimba K, Turner A, Francis H, Lebughe I, Van der Stuyft P, Piot P, 1990. Incidence of malaria and efficacy of oral quinine in patients recently infected with human immunodeficiency virus in Kinshasa, Zaire. J Infect 21: 167-173.
5. Muller O, Moser R, 1990. The clinical and parasitological presentation of Plasmodium falciparum malaria in Uganda is unaffected by HIV-1 infection. Trans R Soc Trop Med Hyg 84: 336-338.
6. Birku Y, Mekonnen E, Bjorkman A, Wolday D, 2002. Delayed clearance of Plasmodium falciparum in patients with human immunodeficiency virus co-infection treated with artemisinin. Ethiop Med J 40 (Suppl 1): 17-26.
7. Kamya MR, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, Francis D, Rosenthal PJ, Dorsey G, Havlir D, 2006. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis 193: 9-15.
8. Van Geertruyden JP, Mulenga M, Mwananyanda L, Chalwe V, Moerman F, Chilengi R, Kasongo W, Van OC, Dujardin JC, Colebunders R, Kestens L, D'Alessandro U, 2006. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis 194: 917-925.
9. Shah SN, Smith EE, Obonyo CO, Kain KC, Bloland PB, Slutsker L, Hamel MJ, 2006. HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. J Infect Dis 194: 1519-1528.
10. Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, Niare-Doumbo S, Coulibaly D, Kone AK, Cissoko Y, Tekete M, Fofana B, Dicko A, Diallo DA, Wellems TE, Kwiatkowski D, Plowe CV, 2003. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 69: 558-563.
11. van Oosterhout JJ, Laufer MK, Graham SM, Thumba F, Perez MA, Chimbiya N, Wilson L, Chagomerana M, Molyneux ME, Zijlstra EE, Taylor TE, Plowe CV, 2005. A community-based study of the incidence of trimethoprim-sulfamethoxazole - preventable infections in Malawian adults living with HIV. J Acquir Immune Defic Syndr 39: 626-631.
12. Beales PF, Brabin B, Dorman E, Gilles HM, Loutain L, Marsh K, Molyneux ME, Olliaro P, Schapira A, Touze JE, Hien TT, Warrell DA, White N, 2000. Severe falciparum malaria. Trans R Soc Trop Med Hyg 94: S1-S90.
13. World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Geneva: WHO.
14. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185: 380-388.
15. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G, 2003. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg 68: 133-139.
16. Van Geertruyden JP, Mulenga M, Kasongo W, Polman K, Colebunders R, Kestens L, D'Alessandro U, 2006. CD4 T-cell count and HIV-1 infection in adults with uncomplicated malaria. J Acquir Immune Defic Syndr 43: 363-367.
17. Plowe CV, Kublin JG, Dzinjalamala FK, Kamwendo DS, Mukadam RA, Chimpeni P, Molyneux ME, Taylor TE, 2004. Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. BMJ 328: 545.
18. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV, 2006. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355: 1959-1966.
19. Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV, 2001. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 358: 1066-1067.
20. Guyatt HL, Snow RW, 2004. The management of fevers in Kenyan children and adults in an area of seasonal malaria transmission. Trans R Soc Trop Med Hyg 98: 111-115.
21. Amin AA, Marsh V, Noor AM, Ochola SA, Snow RW, 2003. The use of formal and informal curative services in the management of paediatric fevers in four districts in Kenya. Trop Med Int Health 8: 1143-1152.